Resources for Community Oncologists on Specialized Immunotoxicity Management

The management of immune-related adverse events associated with cancer immunotherapy is a rapidly evolving challenge, particularly for busy community oncologists and general practitioners. While essential guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) exist, there is a recognized need for more immediately accessible and curated resources to support point-of-care decision-making.

The central challenge identified is determining the minimum, high-yield information needed for clinicians to manage patients effectively in real-time. Academic centers are actively exploring models for integrating rheumatology and other subspecialties into oncology care. Furthermore, initiatives like ASPIRE are working to compile lists of key articles to supplement guidelines, easing the burden of searching for critical information.

The current landscape is described as having "no 1 great resource," but significant efforts are underway to streamline expert knowledge from various subspecialties into a cohesive, easily digestible format for all practitioners.

At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Alexa Meara, MD, explored the interface of oncology and rheumatology in the immunotoxicity management context in her presentation entitled, “Current vs. Ideal Management of IO Toxicities: Rheumatologist Perspective.”

In an interview with Targeted Oncology®, Meara, clinical associate professor of Internal Medicine and rheumatologist at the Ohio State University Wexner Medical Center, spoke about some of the educational resources available to oncologists, and how they can be used to prepare for immunotoxicity events.

To read the full interview with Dr Meara, click here.